BRPI0514466A - composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante - Google Patents
composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberranteInfo
- Publication number
- BRPI0514466A BRPI0514466A BRPI0514466-3A BRPI0514466A BRPI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting
- composition
- methods
- cell
- control point
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000001235 sensitizing effect Effects 0.000 title abstract 2
- 230000004543 DNA replication Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 230000002759 chromosomal effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000005204 segregation Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60296804P | 2004-08-19 | 2004-08-19 | |
| PCT/US2005/029518 WO2006021002A2 (en) | 2004-08-19 | 2005-08-18 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514466A true BRPI0514466A (pt) | 2008-06-10 |
Family
ID=35744692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514466-3A BRPI0514466A (pt) | 2004-08-19 | 2005-08-18 | composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080318974A1 (enExample) |
| EP (1) | EP1778648A2 (enExample) |
| JP (1) | JP2008510719A (enExample) |
| KR (1) | KR20070054205A (enExample) |
| CN (1) | CN101115727A (enExample) |
| AU (1) | AU2005272586A1 (enExample) |
| BR (1) | BRPI0514466A (enExample) |
| CA (1) | CA2577880A1 (enExample) |
| MX (1) | MX2007002040A (enExample) |
| WO (1) | WO2006021002A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA2949793C (en) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN104628659A (zh) * | 2015-01-27 | 2015-05-20 | 广西师范大学 | 具有抗肿瘤作用的吡嗪-芳基脲衍生物及其制备方法与应用 |
| US10570119B2 (en) * | 2016-01-11 | 2020-02-25 | Merrimack Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and Rad3-related protein (ATR) |
| JP6794609B2 (ja) | 2016-02-04 | 2020-12-02 | ファーマエンジン インコーポレーテッドＰｈａｒｍａｅｎｇｉｎｅ， Ｉｎｃ． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途 |
| KR20190130621A (ko) | 2017-03-31 | 2019-11-22 | 시애틀 지네틱스, 인크. | Chk1 저해제와 wee1 저해제의 조합물 |
| KR20200144579A (ko) | 2018-05-14 | 2020-12-29 | 어리어드 파마슈티칼스, 인코포레이티드 | 피리미딘 유도체의 약학 염 및 장애의 치료 방법 |
| WO2021104461A1 (zh) * | 2019-11-29 | 2021-06-03 | 南京明德新药研发有限公司 | 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用 |
| WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL254871A (enExample) * | 1959-08-14 | |||
| CH152169A4 (enExample) * | 1969-01-31 | 1970-11-13 | ||
| US4071524A (en) * | 1976-11-08 | 1978-01-31 | Riker Laboratories, Inc. | Derivatives of urea |
| DE1049664T1 (de) * | 1997-12-22 | 2001-05-03 | Bayer Corp., Pittsburgh | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CN1882342A (zh) * | 2003-09-17 | 2006-12-20 | 艾科斯有限公司 | Chk1抑制剂在控制细胞增殖中的应用 |
| WO2006012308A1 (en) * | 2004-06-25 | 2006-02-02 | Icos Corporation | Bisarylurea derivatives useful for inhibiting chk1 |
| BRPI0512891A (pt) * | 2004-07-02 | 2008-04-15 | Icos Corp | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano |
-
2005
- 2005-08-18 BR BRPI0514466-3A patent/BRPI0514466A/pt not_active IP Right Cessation
- 2005-08-18 CA CA002577880A patent/CA2577880A1/en not_active Abandoned
- 2005-08-18 JP JP2007528037A patent/JP2008510719A/ja active Pending
- 2005-08-18 WO PCT/US2005/029518 patent/WO2006021002A2/en not_active Ceased
- 2005-08-18 KR KR1020077006216A patent/KR20070054205A/ko not_active Withdrawn
- 2005-08-18 AU AU2005272586A patent/AU2005272586A1/en not_active Abandoned
- 2005-08-18 US US11/659,389 patent/US20080318974A1/en not_active Abandoned
- 2005-08-18 CN CNA2005800353820A patent/CN101115727A/zh active Pending
- 2005-08-18 MX MX2007002040A patent/MX2007002040A/es not_active Application Discontinuation
- 2005-08-18 EP EP05810303A patent/EP1778648A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006021002A3 (en) | 2006-04-20 |
| KR20070054205A (ko) | 2007-05-28 |
| AU2005272586A1 (en) | 2006-02-23 |
| WO2006021002A2 (en) | 2006-02-23 |
| US20080318974A1 (en) | 2008-12-25 |
| EP1778648A2 (en) | 2007-05-02 |
| MX2007002040A (es) | 2008-01-11 |
| CA2577880A1 (en) | 2006-02-23 |
| JP2008510719A (ja) | 2008-04-10 |
| CN101115727A (zh) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512891A (pt) | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano | |
| BRPI0514466A (pt) | composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante | |
| NO20074944L (no) | Heteroarylureaderivater anvendlige for inhibering av CHK1 | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| BRPI0517497A (pt) | derivados de azol com atividade antimuscarìnica | |
| BRPI0515477A (pt) | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) | |
| BRPI0416605A (pt) | composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica | |
| IS6935A (is) | Arýl og heteróarýl úrea CHK1 hindrar til að nota sem geislunarnæmar og efnameðferðarnæmar | |
| BR0312464A (pt) | Inibidores de tirosina quinases | |
| BRPI0515499A (pt) | derivados de piridina para a inibição de estearoil-coa-desaturase humana | |
| BRPI0408150A (pt) | composto, seu uso e processo para preparação do mesmo, métodos para tratamento ou profilaxia de cáncer e para produção de um efeito inibidor do ciclo celular (anti - proliferação celular) em um animal de sangue quente e composição farmacêutica | |
| EA201100079A1 (ru) | Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора | |
| NO20090631L (no) | Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser | |
| BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
| BR0317455A (pt) | Derivados de pirrol-pirazol substituìdos como inibidores de quinase | |
| BR0108879A (pt) | Derivado de pirimidina, processo para preparar um derivado de pirimidina compósição farmacêutica, uso de um derivado de pirimidina,e, método para produzir um efeito inibidor do ciclo celular, anti-câncer (anti-proliferação celular) e/ou um efeito inibidor de fak (anti-migração celular e/ou indutor da apoptose) em um animal de sangue quente | |
| BRPI0108841B8 (pt) | derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BR9807995A (pt) | Derivados de 1,5-diidro-pirazol(3,4-d)-pirimidinona | |
| BRPI0510409A (pt) | heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase | |
| ATE430743T1 (de) | Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |